# Biobank-Scale Plasma Proteomics Identifies Novel Biomarkers in Hypertrophic Cardiomyopathy

**Jonathan H Chan<sup>a,b</sup>, Christopher Grace<sup>a,b</sup>, Mohsen Mazidi<sup>c</sup>, Robert Clarke<sup>c</sup>, Carolyn Y. Ho<sup>d</sup>, Stefan Neubauer<sup>a</sup>, Christopher M. Kramer<sup>e</sup> on behalf of HCMR Investigators, Hugh Watkins<sup>a,b</sup>, Anuj Goel<sup>a,b</sup>**

---

## Affiliations

<sup>a</sup> Division of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, UK
<sup>b</sup> Centre for Human Genetics, University of Oxford, Oxford, UK
<sup>c</sup> Nuffield Department of Population Health, University of Oxford, Oxford, UK
<sup>d</sup> Cardiovascular Division, Department of Medicine and Department of Radiology, Brigham and Womenâ€™s Hospital, Boston, MA
<sup>e</sup> Cardiovascular Division, University of Virginia Health System, Charlottesville

---

## Corresponding Author

**Anuj Goel**
- Email: anuj.goel@cardiov.ox.ac.uk
- Address: Level 6 West Wing, John Radcliffe Hospital, Headington, Oxford, OX3 9DU, UK

---

## Abstract ðŸ“œ

### Background
Hypertrophic cardiomyopathy (HCM) is characterized by substantial heterogeneity in both clinical phenotype and risk of adverse outcomes including heart failure and sudden cardiac death. This highlights the need for robust biomarkers for risk stratification and while previous studies have identified the role of select plasma proteins, comprehensive large-scale proteomic analyses have been limited in HCM.  

### Methods
We performed case-control analysis of 2922 plasma proteins in 49,588 UK Biobank participants (100 HCM cases) to identify proteins associated with HCM. External replication analyses were performed in the deCODE Genetics Icelandic study (51 cases/38,904 controls) and All of Us (546 cases/41,049 controls) datasets. Associations with adverse clinical outcomes and cardiac endophenotypes of disease severity were further identified, and causal relationships evaluated using Mendelian randomisation. Relative biomarker importance was also assessed by joint modelling via machine learning. 

### Results
We identified novel associations between angiopoietin-2 (ANGPT2) and latent transforming growth factor-beta binding protein 2 (LTBP2) with HCM, with both also showing prognostic utility for heart failure-related outcomes in HCM cases. We also confirmed the associations of established biomarkers (e.g. NTproBNP, troponins I and T) with HCM cases, cardiac imaging markers of disease severity, and adverse outcomes. Mendelian randomisation analyses supported a causal effect of HCM on increasing NTproBNP and troponin T levels. 

### Conclusions
This biobank-scale plasma proteomic study in HCM identified **ANGPT2** and **LTBP2** as novel HCM biomarkers with potential diagnostic and prognostic utility. These findings highlight the potential for plasma proteomics to improve risk prediction and provide insight into HCM pathobiology.

---

## Keywords ðŸ”‘

Hypertrophic Cardiomyopathy, Plasma Proteomics, Biomarkers, UK Biobank, Mendelian Randomisation, Machine Learning, NTproBNP, Troponin, HRC, ACE2, Risk Stratification, Cardiac Imaging.

---
